Complementarity-determining region (CDR) implantation: a theme of recombination.
A novel technology in the area of antibody engineering has been developed which allows for the creation of new types of antibody molecules. It is called complementarity-determining region (CDR) implantation and permits the random combination of CDR sequences formed in vivo into a single master framework. Thus, totally new gene combinations can be produced and used in selection processes. The result is a genetic variability which is extremely large, even exceeding the natural variability found in the immune system. In this commentary, CDR implantation is presented and the technology is discussed.
Söderlind
E
E
BioInvent Therapeutic AB, Lund, Sweden. es@bioinvent.com
Ohlin
M
M
Carlsson
R
R
D000818:Animals; D000906:Antibodies / Q000235:genetics* / Q000276:immunology; D005803:Genes, Immunoglobulin; D014644:Genetic Variation; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000235:genetics*; D015202:Protein Engineering / Q000379:methods*; D011995:Recombination, Genetic
D000906:Antibodies; D007135:Immunoglobulin Variable Region